BioCentury
ARTICLE | Clinical News

MiR-103/107: Phase I started

January 25, 2016 8:00 AM UTC

AstraZeneca began a single-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of subcutaneous AZD4076 in about 48 healthy male volunteers. The trial start triggered a $10...